Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study retrospectively evaluated the effectiveness of off-label baricitinib in children with severe alopecia areata and found that 50% achieved treatment goals, though psychological effects were noted and laboratory abnormalities occurred in 42.86% of patients.

This review discusses the integration of modern and Unani medicine in the management of Benign Prostatic Hyperplasia, highlighting the potential of Unani herbal formulations as promising alternatives with minimal side effects but reports no new clinical results.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

This study found that combining dibenyline and finasteride for symptomatic BPH treatment offered modest improvements with fewer additional side effects compared to each drug alone.

Adding diltiazem to a beta blocker can cause dangerously slow heart rates.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This review discusses valproate-associated hair abnormalities, describing their common and benign nature, and outlines management strategies, though new clinical results are not provided.

This study found that ethanol extract of Thevetia peruviana bark demonstrated significant antinociceptive activity in mice, suggesting potential for developing new analgesic drugs.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

This study found that Bokusoku extract and its compound pentagalloyl glucose inhibited testosterone metabolism and sebum synthesis, suggesting potential therapeutic use for androgen-related acne.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study observed that topiramate treatment in female zebrafish may impair genetic transmission to offspring, reducing expression of certain skeletal development-related genes in embryos.

This case report suggests that discontinuing finasteride, which may affect neurosteroids synthesis, improved seizure control in a woman with temporal lobe seizures.

In this study, baricitinib treatment for severe alopecia areata was associated with complete hair regrowth after 12 months in two patients, suggesting it may be an effective alternative to traditional therapies, although safety and clinical implications need careful consideration.

This study found that octahydrobenzo[c]quinolizin-3-one derivatives, particularly compound 3, were potent and selective inhibitors of the enzyme 5α-reductase type 1.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

Finasteride boosts morphine's pain relief and prevents tolerance and withdrawal in rats.

In this study, the aqueous extract of Eclipta alba and its hydrolyzed fraction showed nootropic activity and reduced stress-induced alterations in rats.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

Propofol-ketamine and propofol-fentanyl are effective and safe for cosmetic surgery sedation.

This study observed that propranolol, flunarizine, and divalproex sodium were equally effective in managing migraine across a three-month period in a group of 84 patients, with various side effects noted among the drug groups.

In this study, chronic finasteride administration in near-term pregnant rats restored baroreflex control of renal sympathetic nerve activity to levels observed in non-pregnant rats.

This study observed that tributyltin pollution induces imposex, reduces reproductive success, and leads to population decline in Ocinebrina aciculata, highlighting its sensitivity compared to other prosobranch species.

In this study, bicalutamide showed promise in managing female pattern hair loss and reducing minoxidil-induced hypertrichosis, though further research is necessary to refine its use and establish its role in treatment.

The article on the stomach-protecting effects of Cibotium barometz hair was retracted due to unreliable data.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

This study found that the estrous cycle influences the effect of the δ-GABAAR agonist THIP in reducing binge drinking behavior in female mice, with receptor expression elevated during diestrus.

In this study, combining baricitinib and prednisone effectively achieved complete hair regrowth in seven out of eight women with very severe alopecia areata, contrasting with less effective results from each drug used alone.